BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.030
+0.080 (4.10%)
At close: Feb 12, 2026, 4:00 PM EST
2.011
-0.019 (-0.92%)
After-hours: Feb 12, 2026, 6:26 PM EST
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $2.54M in the quarter ending September 30, 2025, a decrease of -3.29%. This brings the company's revenue in the last twelve months to $9.47M, up 2.22% year-over-year. In the year 2024, BioNexus Gene Lab had annual revenue of $9.51M, down -2.66%.
Revenue (ttm)
$9.47M
Revenue Growth
+2.22%
P/S Ratio
0.39
Revenue / Employee
$315,500
Employees
30
Market Cap
4.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.51M | -260.16K | -2.66% |
| Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
| Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
| Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
| Dec 31, 2020 | 11.39M | 11.26M | 8,872.03% |
| Dec 31, 2019 | 126.96K | -85.37K | -40.21% |
| Dec 31, 2018 | 212.33K | 104.65K | 97.18% |
| Dec 31, 2017 | 107.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinseo | 3.13B |
| Aemetis | 201.32M |
| FutureFuel | 137.41M |
| Northern Technologies International | 86.20M |
| Flexible Solutions International | 38.56M |
| CN Energy Group. | 35.57M |
| J-Star Holding | 20.05M |
| Bon Natural Life | 18.67M |
BGLC News
- 15 days ago - BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - GlobeNewsWire
- 2 months ago - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - GlobeNewsWire
- 2 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization - GlobeNewsWire
- 2 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene - GlobeNewsWire
- 3 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - GlobeNewsWire
- 3 months ago - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. - GlobeNewsWire
- 7 months ago - BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology - GlobeNewsWire